Citations (14)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Margherita Ratti & Gianluca Tomasello. (2015) Lipegfilgrastim for the prophylaxis and treatment of chemotherapy-induced neutropenia. Expert Review of Clinical Pharmacology 8:1, pages 15-24.
Read now
Read now
Articles from other publishers (13)
Arash Jenabian, Ali Ehsanpour, Seyed Mohammad Reza Mortazavizadeh, Jahangir Raafat, Mohsen Razavi, Adnan Khosravi, Sharareh Seifi, Babak Salimi, Nassim Anjidani & Hamidreza Kafi. (2022) Evaluating the safety and effectiveness of PegaGen® (pegfilgrastim) for the prevention of chemotherapy-induced febrile neutropenia: a post-marketing surveillance study. Supportive Care in Cancer 30:10, pages 8151-8158.
Crossref
Crossref
Jaekyung Cheon, Hyeon-Su Im, Ho-Jin Shin, Inho Kim, Won Sik Lee, Kyung-Hun Lee, Seong Kyu Park, Min Kyoung Kim, Un Jong Choi, Jung Han Kim, IlKyun Lee & Jae-Cheol Jo. (2021) Pegteograstim prophylaxis for chemotherapy-induced neutropenia and febrile neutropenia: a prospective, observational, postmarketing surveillance study in Korea. Supportive Care in Cancer 29:9, pages 5383-5390.
Crossref
Crossref
Axel S. Merseburger, Götz Geiges, Jörg Klier, Martin Wiesholzer & Petra Pichler. (2021) Pooled Analysis on the Effectiveness and Safety of Lipegfilgrastim in Patients With Urological Malignancies in the Real-World Setting. Frontiers in Oncology 11.
Crossref
Crossref
Ken Sasaki, Kensuke Matsuda, Masashi Miyauchi, Akira Honda, Arika Shimura, Yosuke Masamoto & Mineo Kurokawa. (2021) A retrospective analysis on arteritis after administration of granulocyte colony-stimulating factor. Annals of Hematology 100:5, pages 1341-1343.
Crossref
Crossref
Christian Gessner, Karin Potthoff & Nikolaj Frost. (2021) Efficacy and Safety of Lipegfilgrastim in Lung Cancer Patients Receiving Myelosuppressive Chemotherapy in a Real-World Setting: Results of an Analysis of Pooled Data from Two Non-Interventional European Studies. Oncology Research and Treatment 44:3, pages 93-102.
Crossref
Crossref
Andrew R Zullo, Uvette Lou, Sarah E Cabral, Justin Huynh & Christine M Berard-Collins. (2018) Overuse and underuse of pegfilgrastim for primary prophylaxis of febrile neutropenia. Journal of Oncology Pharmacy Practice 25:6, pages 1357-1365.
Crossref
Crossref
Jean Paul Salmon, Martin Smakal, Charisios Karanikiotis, Marek Z. Wojtukiewicz, Yohann Omnes, Lucy DeCosta, Sally Wetten & James O’Kelly. (2018) Febrile neutropenia (FN) and pegfilgrastim prophylaxis in breast cancer and non-Hodgkin’s lymphoma patients receiving high (> 20%) FN-risk chemotherapy: results from a prospective observational study. Supportive Care in Cancer 27:4, pages 1449-1457.
Crossref
Crossref
Florence Van Ryckeghem, Chloë Haverbeke, Wim Wynendaele, Guy Jerusalem, Luc Somers, Anke Van den broeck, Sofie Vingerhoedt & Simon Van Belle. (2018) Real-world use of granulocyte colony-stimulating factor in ambulatory breast cancer patients: a cross-sectional study. Supportive Care in Cancer 27:3, pages 1099-1108.
Crossref
Crossref
Yassine Lalami & Jean Klastersky. (2017) Impact of chemotherapy-induced neutropenia (CIN) and febrile neutropenia (FN) on cancer treatment outcomes: An overview about well-established and recently emerging clinical data. Critical Reviews in Oncology/Hematology 120, pages 163-179.
Crossref
Crossref
Pedro de Jesús Sobrevilla Calvo, Nora Sobrevilla Moreno & Francisco Javier Ochoa Carrillo. (2016) Neutropenia inducida por quimioterapia: el punto de vista del oncólogo. Gaceta Mexicana de Oncología 15:6, pages 344-349.
Crossref
Crossref
Georgi Mihaylov, Zhasmina Mihaylova, Lubos Drgona, Andrea Cipkova, Jan Novak & Roumyana Petrova. (2016) Healthcare resource utilization and G‑CSF use in patients with solid tumors or hematological malignancies hospitalized for febrile neutropenia in Bulgaria, Czech Republic and Slovakia. memo - Magazine of European Medical Oncology 9:3, pages 144-152.
Crossref
Crossref
Xavier Leleu, Evangelos Terpos, Ramón García Sanz, Julian Cooney, Peter O'Gorman, Jiri Minarik, Richard Greil, Catherine Williams, Diep Gray & Zsolt Szabo. (2016) An international, multicenter, prospective, observational study of neutropenia in patients being treated with lenalidomide + dexamethasone for relapsed or relapsed/refractory multiple myeloma (RR-MM). American Journal of Hematology 91:8, pages 806-811.
Crossref
Crossref
Radosław Mądry, Lidia Popławska, Ferdinand Haslbauer, Martin Šafanda, Doru Ghizdavescu, Jana Benkovicova, Tibor Csőszi, Georgi Mihaylov, Daniela Niepel, Christine Jaeger, Iveta Frkanova, Alina Macovei & Christine Staudigl. (2016) Results of a prospective dose intensity and neutropenia prophylaxis evaluation programme (DIEPP) in cancer patients at risk of febrile neutropenia due to myelosuppressive chemotherapy. Wiener klinische Wochenschrift 128:7-8, pages 238-247.
Crossref
Crossref